Health · Medical Research · 10 hrs ago
Early biomarker responses to resmetirom linked to improved MASH outcomes
Early blood and imaging changes were linked to improved liver outcomes in patients treated with resmetirom.
The drug is also known by the brand name Rezdiffra.
The patients had metabolic dysfunction-associated steatohepatitis, or MASH.
Patients with early biomarker responses were more likely to have MASH resolution.
Those responses were also associated with improvement in liver fibrosis, which means scarring in the liver got better.
The findings show a link, but the information provided does not say that early biomarker changes caused the improvement or what happens next.
Early responses in blood and imaging biomarkers among patients treated with resmetirom were associated with MASH resolution and fibrosis improvement.
The reported findings concern patients treated with resmetirom, also known as Rezdiffra.
The source does not provide details about the study design, number of patients or size of the effects.
MedPage Today published the report on November 9, 2026.
- Who
- Patients treated with resmetirom.
- What
- Early blood and imaging biomarker responses were associated with MASH resolution and fibrosis improvement.
- When
- The report was published on November 9, 2026; the timing of the biomarker responses is not stated.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Resmetirom, also known as Rezdiffra
- Associated outcomes
- MASH resolution and fibrosis improvement
- Publication date
- November 9, 2026